Kenneth J. Hillan, Chief Therapeutics Officer at 23andMe Holding Co. (ME), sold 8,753 shares at $3.64 ($32K) on 2022-08-24, disclosed to the SEC on 2022-08-25.
Open-market sale of $32k ME by Chief Therapeutics Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| AKAO | SELL | 2018-02-23 | $49K | — | Filing → |
| AKAO | SELL | 2017-03-16 | $164K | — | Filing → |
| AKAO | SELL | 2017-02-23 | $39K | — | Filing → |